Methods and compositions related to targeting tumors and wounds

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The Sanford-Burnham Medical Research Institute patent solves the following problem:

A major obstacle to progress in the treatment of cancer in the relative lack of agents that selectively target cancer while saving on normal tissue. For example, radiation therapy and surgery, and general local treatment, causing substantial damage to normal tissue in the treatment field, resulting in scars and loss of normal tissue. Chemotherapy, compared to the total administered systemically, causing substantial damage to organs such as the bone marrow, mucosae, skin and small intestine, undergo rapid cell turnover and continuous cell division. As a result, undesirable side effects such as nausea, hair loss and drop in blood cell count often occur when a cancer patient being treated with a chemotherapeutic drug. The undesirable side effects that can limit the amount of a drug that can be safely administered, thus hampering survival rate and impacting the quality of patient life.

Our analysis of this patent is as follows:

Sanford-Burnham Medical Research Institute’s patent US 8815804 B2 deals with Methods and compositions related to targeting tumors and wounds.
Disclosed compositions and methods useful for targeting tumors, areas of damage and blood clots. The compositions and methods based on peptide sequences that selectively bind and family of tumors, areas of damage and blood clots in animals. The declared target is useful for delivering therapeutic agents and detect tumors, areas of damage and blood clots.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Microbial delivery system

File for Quick & Easy Patent Protection with PowerPatent.

The Allertein Therapeutics, Llc patent solves the following problem:

Allergic reactions pose serious problems to public health worldwide. Pollen allergies (allergic rhinitis or hay fever) affects about 10-15% of the population, and a large economic costs. For example, the report estimates that pollen allergies generated $ 1.8 billion in direct and indirect costs in the United States in 1990 (Fact Sheet, National Institute of Allergy and Infectious Diseases, McMenamin, Annals of Allergy 73:35 , 1994). Asthma, which can be triggered by exposure to antigens, is also a serious problem in public health, and like anaphylactic allergic reactions, can lead to death in severe cases. Asthma is caused by millions of annual visits to the hospital and increasing in frequency. The only treatment currently available for the relief of symptoms, for example, to relieve constriction of airways. More serious than the economic costs associated with pollen and other inhaled allergens (eg, mold, dust mites, animal danders) is the risk of an anaphylactic allergic reaction observed with allergens such as allergens foods, insect venoms, drugs, and latex.

Our analysis of this patent is as follows:

Allertein Therapeutics, Llc’s patent US 8815251 B2 deals with Microbial delivery system.
The present invention provides methods and compositions for treating or preventing allergic responses, particularly anaphylactic allergic responses in subjects allergic to allergens or susceptible to allergies. Methods of the present invention using administration of micro-organisms members, whereby microorganisms and allergens and protect the members from exposure to allergens until phagocytosed antigen-presenting cells. Particularly preferred microorganisms are program-negative bacteria, gram-positive bacteria, and yeast. Particularly preferred allergens are proteins found in foods, venoms, drugs and latex allergic reactions and anaphylactic allergic reactions in people who are allergic to proteins or susceptible to allergies to proteins. The protein may also be modified to reduce the ability of the protein to bind and crosslink IgE antibody and thus reduce the risk of eliciting anaphylaxis without affecting T-cell mediated Th1-type immunity.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Technion Research & Development Foundation Ltd. patent solves the following problem:

Lysyl oxidase (LO or LOX) is a copper containing examine oxidase that oxidizes the first wet substrates reactive aldehydes. LOX catalyzes oxidative deamination of peptidyl lysine and hydroxylysine residues in collagens, and peptidyl lysine residues in elastin, and help build the extracellular matrix. The result peptidyl adelydes usually brief and undergo oxidation reactions to form the lysine-derived covalent cross-links needed for normal structural integrity of the extracellular matrix. Hydrogen peroxide (H2O2) and ammonium usually released in quantities stoichiometric products peptidyl aldehyde. LOX can oxidize some lysine residues in collagen and elastin outside the cell; However, it may also act intracellularly, which regulate gene expression. Furthermore, LOX can induce chemotaxis in monocytes, fibroblasts and smooth muscle cells. LOX itself can trigger a number of growth factors and steroids such as TGF-, TNF- and interferon (Csiszar, program Nucl Acid Res 70: 1-32 (2001)). LOX is involved in various biological functions such as developmental regulation, tumor suppression, cell motility, and cellular senescence. The different roles of LOX and the recently discovered amino oxidase family, lysyl oxidase-related or lysyl oxidase-like protein (lor or LOXL), may play an important role with respect to their intracellular and extracellular localization.

Our analysis of this patent is as follows:

Technion Research & Development Foundation Ltd.’s patent US 8815824 B2 deals with Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis.
The present disclosure provides pharmaceutical compositions and methods useful for modulating angiogenesis and for inhibiting metastasis, inflammation, pulmonary alveolar proteinosis, and fibrosis in a mammal tissues. Pharmaceutical compositions and methods include the inhibitor LOXL2 expression and activity, such as the shRNA target LOXL2.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Myeloid differentiation inducing agents

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Case Western Reserve University patent solves the following problem:

Acute myeloid leukemia (AML) is a wide range of diseases all characterized by leukemic cells have a difference arrest. AML can be classified morphologically as the French-American-British criteria for the kind of divisions as well as the size of cell maturation as M0-M7. Treatment for all subtypes of AML are very similar, except for acute promyelocytic leukemia (APL, M3 subtype). Traditional therapy includes systemic combination chemotherapy. Several different methods are used; However, they often include an induction therapy with cytarabine and a second chemotherapeutic, such as daunorubicin or idarubicin and consolidation therapy with a bone marrow transplant or additional chemotherapy. Besides the significant impact on the traditional chemotherapeutics, the efficacy of these agents in the treatment of AML poor.

Our analysis of this patent is as follows:

Case Western Reserve University’s patent US 8815827 B2 deals with Myeloid differentiation inducing agents.
Myeloid differentiating agent can be used to treat myeloid disorder.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Double-stranded oligonucleotides

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Life Technologies Corporation patent solves the following problem:

Complementary oligonucleotide sequences in the promising therapeutic agents and useful research tools in elucidating gene function. However, oligonucleotide molecules by art is often subject to nuclease degradation when applied to biological systems. Therefore, it is often difficult to achieve efficient inhibition of gene expression (including protein synthesis) in the use of these compositions.

Our analysis of this patent is as follows:

Life Technologies Corporation’s patent US 8815821 B2 deals with Double-stranded oligonucleotides.
Antisense sequences, including the duplex RNAi compositions, that have improved properties designated by a declared. invention provides optimized antisense oligomer composition and methods of making and using the two systems in vitro and therapeutically. the invention also provides methods of making and using the improved antisense oligomer composition.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Methods for treating immune-mediated Dengue Fever infections and antibody-dependent enhancement of Dengue Fever infections, including Dengue Hemorrhagic Fever and Dengue Shock Syndrome

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The Trinity Therapeutics, Inc. patent solves the following problem:

Humoral immune responses to the cause when an antigen binds specifically to an antibody. The combination of an antibody molecule and an antigen forms a small, relatively soluble immune complex. Antigens to be foreign objects, such as viral or bacterial peptides, or be self-antigens such as polypeptides normally found in the human body. The immune system normally distinguishes foreign antigens to self-antigens. Many autoimmune diseases may occur, however, when this system breaks down, the immune system turns on the body and destroys tissues or organ systems as if they were foreign objects. The larger immune complexes more pathogenic than the small, soluble immune complexes. The formation of large, relatively insoluble immune complexes result from the interaction of antibody molecules on antigen and the interaction of the antibody molecules to one another. The immune complexes also result from the interaction between the antibody to the antigen.

Our analysis of this patent is as follows:

Trinity Therapeutics, Inc.’s patent US 8815813 B2 deals with Methods for treating immune-mediated Dengue Fever infections and antibody-dependent enhancement of Dengue Fever infections, including Dengue Hemorrhagic Fever and Dengue Shock Syndrome.
Polypeptides and other compounds that bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, as well as methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation of viral infection, is described. For example, polypeptides and other compounds can be used to inhibit value of DF-associated immune complex IgG anti-DF viron (s) or DV viral antigens in FR, Ade DF / DHF / DSS infections by forbidding DF viral antigen bind to IgG immune complex, FR and immune complex IgG mC1q (membrane C1q) or melt sealing C1q.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Method for rapid detection and identification of bioagents in epidemiological and forensic investigations

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Ibis Biosciences, Inc. patent solves the following problem:

The ease with which small nations and terrorist groups now have biological warfare agents has increased the need to provide the war fighter and civilians alike with miniature, easy to use, disposable instruments for the detection and identification of potentially harmful biological agents (Iqbal et al. Biosensors & Bioelectronics 2000, 15, 549-578; Christel, LA, et al J. Biomech Eng 1999, 121, 22 -27; ……. Higgins, JA, et al Ann NY Acad Sci 1999, 894, 130-148, and Hood, E. around Health Perspect 1999, 107, 931-932) … Traditional methods for the detection and identification of microorganisms, viruses and / or their products lack the speed and feeling of the field since they are not real time or even usually completed in one day. Microbial and viral identification assays have as their basis the principle that dates back to the days of Pasteur, ie the growth of the organism in culture or the replication of virus in a suitable host (Reischl, U., Frontiers Biosci., 1996, 1, Using molecular biology-based approach to the diagnosis of infectious diseases. 1, e72-E77). Toxin identification often rely on biological assays, although relatively rapidly, often need cleaning thread by trials (Feng, P. mol Biotechnol 1997, 7, 267-278; … Van der Zee, H . et al J. AOAC Int. 1997, 80, 934-940). Depending on the nature of the agents noted, this process can be from days to months (Pillai, SD Arch Virol 1997, 13 Suppl, 67-82; … Van der Zee, H. et al J. AOAC Int .. 1997, 80, 934-940). Clearly, this is not practical in situations where detection and recognition may be needed to protect a population from harmful biological agents. Molecular systems of knowledge that can be used for the rapid identification can improve response time and thus avoid or reduce the number of casualties associated with a potential bioterrorism or biowarfare incident.

Our analysis of this patent is as follows:

Ibis Biosciences, Inc.’s patent US 8815513 B2 deals with Method for rapid detection and identification of bioagents in epidemiological and forensic investigations.
The present invention provides methods for rapid forensic investigation by identifying bioagents associated with biowarfare and acts of terrorism or crime. The method is useful for epidemiological investigation by genotyping bioagents.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Modulation of signal transducer and activator of transcription 3 (STAT3)expression

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Isis Pharmaceuticals, Inc. patent solves the following problem:

The stat (signal transducers and activators of transcription) family proteins are the DNA-binding proteins that play a role two signal transduction and activation of transcription. At present, there are six different members of the family stat (stat1, stat2, Stat3, STAT4, STAT5, and STAT6) and some isoforms (stat1, stat1, Stat3 and Stat3). The activities of these stats are modulated in various cytokines and mitogenic stimuli. Binding of a cytokine to its receptor results in activation of Janus protein tyrosine kinases (Jaks) associated with this receptor. It phosphorylates stat, which resulted in the transition to the nucleus and transcriptional activation of STAT responsive gene. Phosphorylation of specific tyrosine residue on the results stats in their activation, resulting in the formation of homodimers and / or heterodimers stat that bind to specific sequences gene promoter. Events mediated by cytokines by stat activation including cell proliferation and diversity and to avoid apoptosis.

Our analysis of this patent is as follows:

Isis Pharmaceuticals, Inc.’s patent US 8816056 B2 deals with Modulation of signal transducer and activator of transcription 3 (STAT3)expression.
Said here that the antisense compounds and methods for reducing Stat3 mRNA and protein expression. The methods, compounds and compositions are useful to treat, prevent, or reduce the hyperproliferative diseases.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Modulated reflectance measurement system using UV probe

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Kla-Tencor Corporation patent solves the following problem:

There is a great need in the semiconductor industry in metrology equipment to provide high resolution, nondestructive evaluation wafers products while they are in various fabrication. In recent years, a number of products for the nondestructive evaluation of semiconductor sample. One such product to market successfully by the Assignee herein under the trademark Therma-Probe. Dodge This includes technology described in the following US Pat. Nos 4,634,290. 4,646,088; 5,854,710; 5,074,669 and 5,978,074. Each of these patents are incorporated here by reference.

Our analysis of this patent is as follows:

Kla-Tencor Corporation’s patent US 8817260 B2 deals with Modulated reflectance measurement system using UV probe.
A modulated reflectance measurement system includes laser for generating an intensity modulated pump beam and a UV beam investigation. The pump and probe beams focused on a measure to place in a sample. The pump beam every awakens to measure modulation site and delivered to the probe beam. For one embodiment, the wavelength of the probe beam that chose the equivalent of a local temperature maxima to reflect coefficient of sample. For a second image, the probe laser listened to reduce the heat wave contribution to the probe beam modulation or to equalize the heat, and contributions to plasma wave investigation beam modulation.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Vehicle guidance system with interface

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Ford Global Technologies, Llc patent solves the following problem:

Battery electric vehicles (BEVs) and plug-in hybrid electric vehicles (PHEVs) can be connected to an external power supply for charging a car battery. Such vehicles often include a charge cord that extends from an external power supply, and physically connected to a car charging dock to facilitate giving the car battery. However, the command line prone to operator error. For example, if the user fails to properly connect to the service line, or forget to connect the charge cord completely, then the battery will not charge. Moreover, the user can charge cord damage or car if he forgets to disconnect the charge cord before driving from the external power supply. Moreover, the duty cords should be stored in a safe place when not in use. For example, the duty cord can be damaged if the user leaves the office land line and inadvertently drives over it.

Our analysis of this patent is as follows:

Ford Global Technologies, Llc’s patent US 8816637 B2 deals with Vehicle guidance system with interface.
A vehicle guidance system provided a controller configured to receive the input signal indicates a continual charging dock position relative to an external charging pad and a charging status. The controller further configured to pass a vehicle condition signal in response to the input signal. An interface communicates with the controller and configured to display a vehicle position indicator and a charging status message in response to the signal status car.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.